Home » Stocks » DTIL

Precision BioSciences, Inc. (DTIL)

Stock Price: $13.29 USD -0.29 (-2.14%)
Updated Jan 22, 2021 4:00 PM EST - Market closed
After-hours: $14.29 +1.00 (7.52%) Jan 22, 7:59 PM
Market Cap 747.47M
Revenue (ttm) 21.96M
Net Income (ttm) -106.47M
Shares Out 52.35M
EPS (ttm) -2.06
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 22
Last Price $13.29
Previous Close $13.58
Change ($) -0.29
Change (%) -2.14%
Day's Open 13.64
Day's Range 12.85 - 13.70
Day's Volume 1,787,682
52-Week Range 4.65 - 14.64

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Zacks Investment Research - 3 days ago

The FDA accepts Precision BioSciences' (DTIL) regulatory application to initiate a clinical study on its next-generation CD19 product candidate, PBCAR19B.

Benzinga - 4 days ago

Cocrystal Pharma (NASDAQ: COCP) shares are trading higher after the company announced it has completed all research obligations under the Merck exclusive worldwide license and collaboration ag...

Other stocks mentioned: COCP
GlobeNewsWire - 4 days ago

Phase 1 clinical trial of PBCAR19B for patients with relapsed/refractory NHL expected to begin by mid-2021 Phase 1 clinical trial of PBCAR19B for patients with relapsed/refractory NHL expected...

GlobeNewsWire - 2 weeks ago

DURHAM, N.C., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company dedicated to improving life with its novel and proprietary AR...

Seeking Alpha - 1 month ago

DTIL has three business lines, all of which include important collaborations with large companies. Recent results in CAR-T therapies have been very encouraging.

GlobeNewsWire - 1 month ago

DURHAM, N.C., Dec. 14, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage biotechnology company dedicated to improving life with its novel and proprietary ARC...

GlobeNewsWire - 1 month ago

Acceptable Toler ability and Safety Profile in 27 Patients with No Graft versus Host Disease (GvHD), No Grade ≥ 3 Cytokine Release Syndrome (CRS) , and No Grade ≥ 3 Neurotoxicity (ICANS)

GlobeNewsWire - 1 month ago

DURHAM, N.C., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company dedicated to improving life with its novel and proprietary AR...

PRNewsWire - 2 months ago

INDIANAPOLIS, and DURHAM, N.C., Nov. 20, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Precision BioSciences, Inc. (Nasdaq: DTIL) today announced a research collaboration and excl...

Other stocks mentioned: LLY
Zacks Investment Research - 2 months ago

Precision BioSciences (DTIL) delivered earnings and revenue surprises of 26.47% and 73.25%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for...

Benzinga - 2 months ago

Shares of Precision BioSciences (NASDAQ:DTIL) remained unaffected after the company reported Q3 results. Quarterly Results Earnings per share were down 21.95% year over year to ($0.50), which ...

GlobeNewsWire - 2 months ago

Expanded allogeneic CAR T development collaboration with Servier to include four new programs targeting hematological and solid tumors

Zacks Investment Research - 2 months ago

Precision BioSciences (DTIL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 2 months ago

DURHAM, N.C., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical-stage biotechnology company dedicated to improving life with its novel and proprietary AR...

Seeking Alpha - 2 months ago

Precision BioSciences, Inc. is a life sciences company focused on utilizing its ARCUS genome editing platform to primarily treat human diseases and secondarily to provide food/agricultural sol...

GlobeNewsWire - 3 months ago

PTAB Rules in Favor of Precision BioSciences in Two Patent Interference Proceedings PTAB Rules in Favor of Precision BioSciences in Two Patent Interference Proceedings

GlobeNewsWire - 3 months ago

DURHAM, N.C., Oct. 14, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction thera...

GlobeNewsWire - 3 months ago

DURHAM, N.C., Sept. 28, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction th...

GlobeNewsWire - 4 months ago

Increasing BCMA Surface Expression and Reduced Soluble BCMA Levels with Gamma Secretase Inhibitor Nirogacestat May Enhance Clinical Benefit in Combination with PBCAR269A, an Allogeneic BCMA-Ta...

24/7 Wall Street - 4 months ago

A key update from the U.S. Food and Drug Administration (FDA) boosted Precision BioSciences Inc.

GlobeNewsWire - 4 months ago

DURHAM, N.C., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company dedicated to improving life with its novel and proprietary...

GlobeNewsWire - 4 months ago

DURHAM, N.C., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company dedicated to improving life with its novel and proprietary...

GlobeNewsWire - 5 months ago

DURHAM, N.C., Aug. 19, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company dedicated to improving life with its novel and proprietary ...

Zacks Investment Research - 5 months ago

Precision BioSciences (DTIL) delivered earnings and revenue surprises of -5.00% and -80.81%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the...

Benzinga - 5 months ago

Shares of Precision BioSciences (NASDAQ:DTIL) were unchanged after the company reported Q2 results.

GlobeNewsWire - 5 months ago

Dosed First Patient in Phase 1/2a Clinical Trial of PBCAR269A, a BCMA-Targeted Allogeneic CAR T Candidate for Multiple Myeloma

Zacks Investment Research - 5 months ago

Precision BioSciences (DTIL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 5 months ago

DURHAM, N.C., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company dedicated to improving life with its novel and proprietary ...

GlobeNewsWire - 6 months ago

DURHAM, N.C., July 06, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company dedicated to improving life with its novel and proprietary ...

GlobeNewsWire - 7 months ago

-PBCAR269A Targets BCMA for the Treatment of Relapsed/Refractory Multiple Myeloma and is the Company’s Third Investigational Allogeneic CAR T Candidate Advanced to the Clinic –

Benzinga - 8 months ago

Shares of Precision BioSciences (NASDAQ:DTIL) rose 8.2% in pre-market trading after the company reported Q1 results.

Zacks Investment Research - 8 months ago

Precision BioSciences (DTIL) delivered earnings and revenue surprises of 1.89% and 34.71%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the ...

GlobeNewsWire - 8 months ago

Dosed First Patient in Phase 1/2a Clinical Study of PBCAR20A in Relapsed/Refractory NHL, CLL, and SLL

Zacks Investment Research - 8 months ago

Precision BioSciences (DTIL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 8 months ago

Precision BioSciences (DTIL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

The Motley Fool - 9 months ago

These healthcare stocks are risky, but they offer investors much better wealth-building potential than penny stocks.

Other stocks mentioned: CHRS
GlobeNewsWire - 9 months ago

DURHAM, N.C., April 15, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a life sciences company dedicated to improving life through the application of its pioneering, pr...

GlobeNewsWire - 9 months ago

PBCAR20A targets CD20 and is the Company’s second investigational allogeneic CAR T candidate advanced to the clinic

GlobeNewsWire - 10 months ago

DURHAM, N.C., March 11, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a life sciences company dedicated to improving life through the application of its pioneering, pr...

Seeking Alpha - 10 months ago

Precision BioSciences: Consider Taking Up A Small Position

The Motley Fool - 1 year ago

Investors shouldn't forget that the world of biotech extends beyond biopharmaceuticals.

Other stocks mentioned: CLLS, CLXT
GlobeNewsWire - 1 year ago

-Phase 1 clinical trial of off-the-shelf (allogeneic) anti-BCMA CAR T therapy candidate for patients with relapsed/refractory multiple myeloma expected to begin dosing patients in 2020-

Seeking Alpha - 1 year ago

Precision BioSciences Makes Impressive Progress On Mission To Change CAR-T Therapy Landscape

The Motley Fool - 1 year ago

Find out why one of these stocks lost more than half its value.

Other stocks mentioned: GME, IFF
The Motley Fool - 1 year ago

Investors should remember that CRISPR isn't the only gene editing technology out there. Case in point: ARCUS.

The Motley Fool - 1 year ago

Precision BioSciences provided an expanded update from its first clinical asset. Investors weren't impressed.

Benzinga - 1 year ago

The American Society of Hematology's 61st annual meeting is underway in Orlando, Florida.

Other stocks mentioned: FTSV, MBIO, RHHBY, TGTX
Market Watch - 1 year ago

Shares of Precision BioSciences Inc. are up 13% in premarket trading after it announced positive results from a small Phase 1 clinical trial for its chimeric antigen receptor (CAR) T cell the...

GlobeNewsWire - 1 year ago

- PBCAR0191 continues to be associated with no serious adverse events or dose limiting toxicities observed to date, and no cases of graft-versus-host disease-

Zacks Investment Research - 1 year ago

As of late, it has definitely been a great time to be an investor in Precision BioSciences, Inc. (DTIL).

About DTIL

Precision BioSciences, a genome editing company, develops therapeutic products in the United States. The company operates through two segments, Therapeutic and Food. It offers ARCUS, a genome-editing platform to cure cancers and genetic disorders. The Therapeutic segment develops allogeneic CAR T immunotherapy that recognizes and kills cancer cells; and engages in the in vivo gene correction activities. This segment develops PBCAR0191, which is in Phase 1/2a clinical trial, an allogeneic CAR T cell therapy targeting the tumor target CD19 for ac... [Read more...]

Industry
Biotechnology
IPO Date
Mar 28, 2019
CEO
Matthew Kane
Employees
223
Stock Exchange
NASDAQ
Ticker Symbol
DTIL
Full Company Profile

Financial Performance

In 2019, DTIL's revenue was $22.24 million, an increase of 104.34% compared to the previous year's $10.88 million. Losses were -$92.88 million, 101.7% more than in 2018.

Financial Statements

Analyst Forecasts

According to 8 analysts, the average rating for DTIL stock is "Buy." The 12-month stock price forecast is 15.57, which is an increase of 17.16% from the latest price.

Price Target
$15.57
(17.16% upside)
Analyst Consensus: Buy